Julie Engers
-
Drug discovery efforts continue in latest chemical chronicle from the Warren Center for Neuroscience Drug Discovery
Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read MoreOct 31, 2024
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials. Read MoreDec 4, 2023
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read MoreFeb 22, 2022